Physician profile
Roy N Lemaster
NPI 1629241427
$3,115.54
in general payments reported to CMS, 2019-2025
23 companies · $941 in 2025
The $941 reported for 2025 was more than what 89% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.44 · 2020: $57.19 · 2022: $101 · 2023: $991 · 2024: $952 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,882.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $675.31 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $445.05 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $379.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $321.68 | 2020-2025 | |
| Glaxosmithkline, LLC. | $240.48 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $149.36 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Corium, LLC | $108.02 | 2023 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $107.06 | 2023-2025 | |
| Exact Sciences Corporation | $91.16 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.90 | 2025 | Caplyta |
| Gilead Sciences, INC. | $78.50 | 2019-2020 | |
| Amgen INC. | $77.02 | 2024-2025 | Repatha, Evenity, Prolia |
| Vanda Pharmaceuticals INC. | $71.66 | 2024-2025 | Fanapt, Hetlioz |
| Alk-Abello, INC | $64.88 | 2025 | Grastek, Odactra, Ragwitek |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.06 | 2023-2025 | Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.31 | 2019-2023 | Stiolto Respimat |
| Vapotherm INC | $25.06 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.90 | 2023 | Xarelto |
| Dynavax Technologies Corporation | $24.89 | 2023 | Heplisav-B |
| Photonicare INC | $23.38 | 2023 | Otosight Middle Ear Scope |
| Genentech USA, INC. | $16.67 | 2019 | |
| Axsome Therapeutics, INC. | $16.01 | 2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Lemaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.